Mass balance, pharmacokinetics and pharmacodynamics of intravenous HSK3486, a novel anaesthetic, administered to healthy subjects

Yicong Bian, Hua Zhang, Sheng Ma, Yongyi Jiao, Pangke Yan, Xiao Liu, Shiping Ma, Yating Xiong, Zheming Gu, Zhenwen Yu, Chenrong Huang, Liyan Miao, Yicong Bian, Hua Zhang, Sheng Ma, Yongyi Jiao, Pangke Yan, Xiao Liu, Shiping Ma, Yating Xiong, Zheming Gu, Zhenwen Yu, Chenrong Huang, Liyan Miao

Abstract

Aims: This trial (NCT03751956) investigated the mass balance, pharmacokinetics and pharmacodynamics of HSK3486, a novel anaesthetic, in healthy subjects.

Methods: A single dose of 0.4 mg/kg [14 C]HSK3486 was administered to six healthy subjects. Blood, urine and faecal samples were collected, analysed for radioactivity, unchanged HSK3486 and profiled for metabolites. The Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scale and vital signs were closely monitored during the study.

Results: The mean recovery of total radioactivity in excreta was 87.3% in 240 h, including 84.6% in urine and 2.65% in faeces. The exposure (AUC0-t ) of total radioactivity was much higher than that of unchanged HSK3486 in plasma, indicating there were circulating metabolites in plasma. The glucuronide conjugate of HSK3486 (M4) was found as the only major circulating metabolite in plasma (79.3%), while unchanged HSK3486 accounted for only 3.97% of the total radiation exposure. M4 also resulted in a longer estimated elimination half-life (t1/2 ) of total radioactivity than that of unchanged HSK3486 in plasma. Fortunately, the metabolite was detected to be not specific to red blood cells and was suggested to be nonhypnotic and nontoxic. All the subjects were quickly anaesthetized (2 min) after drug administration and woke up smoothly after a short time (5.5-14.1 min) with few residual effects. The only adverse event in the study was mild (grade 1) and consisted of hypotension.

Conclusion: HSK3486 is a promising anaesthetic candidate with rapid onset of action and clear absorption, distribution, metabolism, excretion (ADME) processes. HSK3486 showed favourable pharmacokinetic characteristics, pharmacodynamic responses and safety at the study dose.

Keywords: HSK3486; anaesthetic; major circulating metabolites; mass balance; pharmacokinetics.

© 2020 The British Pharmacological Society.

References

REFERENCES

    1. Qin L, Ren L, Wan S, et al. Design, synthesis, and evaluation of novel 2,6-disubstituted phenol derivatives as general anesthetics. J Med Chem. 2017;60(9):3606-3617.
    1. Wei Y, Qiu G, Lei B, et al. Oral delivery of propofol with methoxymethylphosphonic acid as the delivery vehicle. J Med Chem. 2017;60(20):8580-8590.
    1. von Richter O, Massimini G, Scheible H, Udvaros I, Johne A. Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients. Br J Clin Pharmacol. 2016;82(6):1498-1508.
    1. Penner N, Xu L, Prakash C. Radiolabeled absorption, distribution, metabolism, and excretion studies in drug development: why, when, and how? Chem Res Toxicol. 2012;25(3):513-531.
    1. Meng J, Liu XY, Ma S, et al. Metabolism and disposition of pyrotinib in healthy male volunteers: covalent binding with human plasma protein. Acta Pharmacol Sin. 2019;40(7):980-988.
    1. Valentin J. The 2007 recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann ICRP. 2007;37(2-4):1-332.
    1. ICRP. Radiation dose to patients from radiopharmaceuticals (addendum 1 to ICRP publication 53). 1992.
    1. US FDA. 21 CFR 361.1. Radioactive Drugs for Certain Research Uses Available from:.
    1. Nijenhuis CM, Schellens JH, Beijnen JH. Regulatory aspects of human radiolabeled mass balance studies in oncology: concise review. Drug Metab Rev. 2016;48(2):266-280.
    1. Hop CE, Wang Z, Chen Q, Kwei G. Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J Pharm Sci. 1998;87(7):901-903.
    1. van Andel L, Zhang Z, Lu S, et al. Human mass balance study and metabolite profiling of (14)C-niraparib, a novel poly (ADP-ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer. Invest New Drugs. 2017;35(6):751-765.
    1. Liao M, Watkins S, Nash E, et al. Evaluation of absorption, distribution, metabolism, and excretion of [(14)C]-rucaparib, a poly (ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2020;38(3):765-775.
    1. Valk BI, Absalom AR, Meyer P, et al. Safety and clinical effect of i.v. infusion of cyclopropyl-methoxycarbonyl etomidate (ABP-700), a soft analogue of etomidate, in healthy subjects. Br J Anaesth. 2018;120(6):1401-1411.
    1. Harding SD, Sharman JL, Faccenda E, et al. The IUPHAR/BPS guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. Nucleic Acids Res. 2018;46(1):D1091-D1106.
    1. Alexander SPH, Mathie A, Peters JA, et al. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels. Br J Pharmacol. 2019;176(Suppl 1):S142-228.
    1. Simons PJ, Cockshott ID, Douglas EJ, Gordon EA, Hopkins K, Rowland M. Disposition in male volunteers of a subanaesthetic intravenous dose of an oil in water emulsion of 14C-propofol. Xenobiotica. 1988;18(4):429-440.
    1. Sahinovic MM, Struys M, Absalom AR. Clinical pharmacokinetics and pharmacodynamics of propofol. Clin Pharmacokinet. 2018;57(12):1539-1558.
    1. Grossherr M, Hengstenberg A, Meier T, Dibbelt L, Gerlach K, Gehring H. Discontinuous monitoring of propofol concentrations in expired alveolar gas and in arterial and venous plasma during artificial ventilation. Anesthesiology. 2006;104(4):786-790.
    1. Kanaya N, Gable B, Wickley PJ, Murray PA, Damron DS. Experimental conditions are important determinants of cardiac inotropic effects of propofol. Anesthesiology. 2005;103(5):1026-1034.
    1. Nagakawa T, Yamazaki M, Hatakeyama N, Stekiel TA. The mechanisms of propofol-mediated hyperpolarization of in situ rat mesenteric vascular smooth muscle. Anesth Analg. 2003;97(6):1639-1645.
    1. Moos DD. Propofol. Gastroenterol Nurs. 2006;29(2):176-178.
    1. Dinis-Oliveira RJ. Metabolic profiles of propofol and fospropofol: clinical and forensic interpretative aspects. Biomed Res Int. 2018;2018:6852857.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel